This is an argument I’ve made, with colleagues, in endless different places. New diabetes drugs are approved with woeful data, small numbers of patients in trials that only measure blood tests, rather than real-world outcomes such as heart attack, renal failure, or death: so let’s roll out new diabetes treatments in the NHS through randomised trials. We rely on observational studies to establish whether Tamiflu reduces complications of pneumonia: that’s silly, we can do trials , and we should. Statin treatment regimes in widespread use have never been compared head-to-head , using real-world outcomes such as heart attack, stroke, and death: so let’s embed randomised trials as cheaply as possible in routine clinical care (we’ve done two pilots , to document the barriers).
Critique is an independent scholarly journal, founded in 1973. It attempts to analyse contemporary society, both East and West, from a critical Marxist perspective. Rejecting the concept of socialism in one country, and the possibility that a country could be both socialist and undemocratic, it seeks to show that the problems of our time are governed by the necessity for democratic control over all aspects of society. The absence of democratic control leads to an inefficient, wasteful and hierarchically structured economy, though in different ways according to the particular society.